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ABSTRACT
Introduction: Extraintestinal manifestations
(EIMs) in patients with Crohn’s disease (CD) are
common and associated with additional mor-
bidity. This study aimed to evaluate the effect of
adalimumab therapy on EIM resolution and
identify potential predictors of EIM resolution
in adult and pediatric patients with moderate to
severe CD.
Methods: EIM data were pooled from 11
induction, maintenance, and open-label exten-
sion studies of adalimumab. Resolution of EIMs
was evaluated at approximately 6 months and
1 year. Median time to initial EIM resolution
and first EIM recurrence (reflecting durable res-
olution) of any EIM and specific categories of
EIMs (arthritis/arthralgia, ocular, cutaneous)
were calculated. A Cox model was used to
determine predictors of initial and durable EIM
resolution.
Results: At baseline, 54% (1137/2094) of
patients receiving adalimumab and 51% (297/
586) receiving placebo had EIMs. EIM resolu-
tion occurred in a significantly greater propor-
tion of adalimumab versus placebo patients at
6 months (54% vs 31%; P\.001) and 1 year
(60% vs 42%; P = .008). Median time to initial
resolution of any EIM, arthritis/arthralgia, and
cutaneous EIMs was significantly shorter in
patients receiving adalimumab versus placebo.
Durable resolution of any EIM and arthritis/
arthralgia was significantly longer for patients
receiving adalimumab versus placebo. Clini-
cally meaningful predictors of EIM resolution
included adalimumab treatment, male sex, and
moderate (versus severe) disease activity at
baseline.
Conclusion: Adalimumab is effective for
achieving initial and durable resolution of any
EIM and, in particular, arthritis/arthralgia in
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patients with moderate to severe CD. Predictors
of EIM resolution included adalimumab treat-
ment and moderate disease severity.
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INTRODUCTION
Although Crohn’s disease (CD) is a chronic,
recurrent inflammatory disease of the digestive
tract, the impact of CD can extend beyond this
primary location. Extraintestinal manifesta-
tions (EIMs), such as arthritis and arthralgia,
are present in up to 70% of patients with CD
and are associated with morbidity and
impaired quality of life [1–6]. Although the
pathogenesis of EIMs remains unclear, some
manifestations appear to be related to the
pathophysiology of inflammatory bowel dis-
ease (IBD) [5, 7].
In CD, the risk of developing EIMs is
increased in patients who smoke, have longer
disease duration, and are younger at diagnosis
[3, 8]. The presence of one EIM may confer a
higher likelihood of developing other EIMs
[7]. Although EIMs that parallel IBD activity
may resolve with treatment of intestinal
inflammation, EIMs that are independent of
intestinal disease activity will likely require
treatment with additional systemic therapies
[6, 9, 10].
Adalimumab, a recombinant human mono-
clonal antibody targeting tumor necrosis factor
(TNF), is effective in the induction and main-
tenance of remission of moderate to severe CD
in adult and pediatric patients [11–14]. The
objectives of this post hoc analysis of pooled
study data from adult and pediatric patients
with moderate to severe CD were to evaluate
the effect of adalimumab therapy on initial and
durable EIM resolution and to describe poten-
tial predictors of initial resolution and first
recurrence of EIMs.
METHODS
Study Designs and Patients
Data related to EIMs were pooled from 11
induction, maintenance, and open-label exten-
sion studies in adult and pediatric patients with
moderate to severe CD (Supplemental Fig. S1).
The methods and primary results of the CD
trials were previously reported (Supplemental
Table S1). This article does not contain any new
studies with human or animal subjects per-
formed by any of the authors [11–22]. Adult
patients were enrolled in one of the following
studies: three double-blind, randomized, pla-
cebo-controlled induction studies (Clinical
assessment of Adalimumab Safety and efficacy
Studied as Induction therapy in Crohn’s disease
[CLASSIC-I; NCT00055523], Gauging Adali-
mumab efficacy in Infliximab Nonresponders
[GAIN; NCT00105300], and M04-729 Japan
[NCT00445939]), including follow-up in their
52-week maintenance or extension studies
(CLASSIC-II [NCT00055497], Additional long-
term Dosing with HUMIRA to Evaluate sus-
tained Remission and Efficacy in CD [ADHERE;
NCT00195715], and M06-837 [NCT00445432],
respectively); two double-blind, randomized,
placebo-controlled, 52-week (extend the safety
and efficacy of adalimumab through endo-
scopic healing [EXTEND; NCT00348283]) or
56-week (Crohn’s trial of the fully Human
antibody Adalimumab for Remission Mainte-
nance [CHARM; NCT00077779]) induction and
maintenance studies; and one 20-week, open-
label study (Crohn’s Treatment with Adali-
mumab: Patient Response to a Safety and Effi-
cacy Study [CARE; NCT00409617]). Pediatric
patients were enrolled in one randomized,
double-blind, 52-week pediatric study (IMA-
gINE 1; NCT00409682) and its open-label
extension (IMAgINE 2; NCT00686374); only
patients at least 13 years old who completed the
Crohn’s Disease Activity Index (CDAI) were
included in this analysis.
Patients included in this analysis had base-
line and postbaseline EIM data. The adali-
mumab group included all patients randomized
to adalimumab, including those who received
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open-label rescue therapy after blinded adali-
mumab treatment or open-label adalimumab in
non-randomized trials. The placebo group
included patients who were randomized to
placebo in the double-blind trials. Patients who
received placebo and were subsequently re-
randomized to blinded adalimumab or received
open-label adalimumab at any point were cen-
sored from that point forward.
EIM Assessment
In 10 studies, assessment of the presence or
absence of EIMs was based on question 4 of the
CDAI, which evaluated these EIM categories:
arthritis or arthralgia, ocular complications
(iritis or uveitis), and cutaneous complications
(erythema nodosum, pyoderma gangrenosum,
or aphthous stomatitis). In the CARE study, the
presence of EIMs was evaluated by the investi-
gator on a separate form [18].
Resolution of EIMs was evaluated in a pooled
analysis of all studies at the time points closest
to 6 months (weeks 20–26) and 1 year (weeks
52–56). Because CARE was a 20-week study, it
was included in the 6-month analysis but not
the 1-year analysis. Corticosteroid-free EIM res-
olution was evaluated at 6 months and 1 year in
patients with EIMs at baseline who also received
corticosteroids at baseline. Time to initial EIM
resolution and time to first EIM recurrence (re-
flecting durable resolution) were calculated for
any EIM and for specific categories of EIMs
(arthritis/arthralgia, ocular, cutaneous). Recur-
rence was defined by the presence of the EIM
after initial resolution.
To identify potential predictors of initial EIM
resolution and first EIM recurrence, these base-
line characteristics were evaluated: sex, age,
disease duration, involved intestinal area, dis-
ease activity (CDAI or Harvey–Bradshaw Index),
albumin (g/L), C-reactive protein (mg/dL),
thiopurine use, corticosteroid use, prior anti-
TNF exposure, and smoking status.
Statistical Analyses
A t test (continuous predictors) or Chi-square
test (categorical predictors) was used to evaluate
potential differences in baseline characteristics
between groups for (1) patients with versus
without EIMs at baseline and (2) placebo versus
adalimumab groups in patients with EIMs at
baseline. Among patients with EIMs and corti-
costeroid use at baseline, corticosteroid-free EIM
resolution (EIM resolution in patients who also
discontinued corticosteroids) was evaluated.
Because of the disproportionately small number
of patients in the placebo group relative to the
adalimumab group, between-group compar-
isons were descriptive only and P values were
not provided. Data are reported as observed.
Median time to initial EIM resolution and
first EIM recurrence following resolution were
evaluated via Kaplan–Meier survival curves with
the log-rank test for between-group compar-
isons; median time to first recurrence of cuta-
neous and ocular EIMs could not be estimated
because of low event numbers. A random-effect
meta-analysis that used the study as a random
effect in a Cox model determined the predictors
of initial and durable EIM resolution in patients
with any EIM or with arthritis/arthralgia.
RESULTS
Patients
The contribution of patients from each of the
included studies is outlined in Supplemental
Table S1 and Supplemental Fig. S1. A total of
54% (1434/2680) of patients had EIMs at base-
line (51% of placebo patients [297/586] and
54% of adalimumab patients [1137/2094]).
Arthritis/arthralgia was present in 51% of
patients (48% of placebo patients [282/586] and
52% of adalimumab patients [1082/2094]) and
represented 95% of all EIMs reported in these
studies (Table 1). Only a small proportion of
patients had ocular (1%; 33/2680) or cutaneous
(6%; 157/2680) EIMs. Nearly all baseline char-
acteristics were significantly different for
patients with EIMs versus those without EIMs;
patients with EIMs were more likely to be
women, smokers, slightly older, with longer
disease duration, and more severe disease
(Table 1). Patients with EIMs were also less likely
to use thiopurines at baseline and more likely to
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Table 1 Patient demographics and baseline disease characteristics
Characteristic Overall ITT population Patients with EIMs at baseline
EIMs at
baseline
No EIMs at
baseline
P value Placebo Adalimumab P value
n5 1434 n5 1246 n5 297 n5 1137
Age, years, mean (SD) 37.8 (12.1) 33.0 (11.7) \ .001 38.9
(11.9)
37.5 (12.2) .090
Female, n (%) 943 (65.8) 646 (51.8) \ .001 196
(66.0)
747 (65.7) .924
Disease duration, years, mean
(SD)
10.4 (8.6)
n = 1433
9.1 (7.6) \ .001 11.0 (8.8)
n = 296
10.3 (8.5) .202
Disease activitya .018 .001
Moderate, n (%) 835 (58.2) 782 (62.8) 149
(50.2)
686 (60.3)
Severe, n (%) 598 (41.7) 464 (37.2) 148
(49.8)
450 (39.6)
Albumin, g/L, mean (SD) 39.7 (5.0) 38.9 (5.3) \ .001 39.6 (4.8) 39.7 (5.0) .701
CRP, mg/dL, mean (SD) 1.9 (2.7)
n = 1421
2.4 (4.3)
n = 1227
\ .001 1.7 (2.7) 1.9 (2.7)
n = 1124
.248
Concomitant medication use at baseline, n (%)
Thiopurine use (AZA/6-MP) 554 (38.6) 548 (44.0) .005 105
(35.4)
449 (39.5) .192
Corticosteroid use 587 (40.9) 503 (40.4) .766 117
(39.4)
470 (41.3) .544
Prior anti-TNF use 736 (51.3) 592 (47.5) .049 186
(62.6)
550 (48.4) \ .001
Current smoker, n (%) 545 (38.0) 411 (33.0) .007 107
(36.0)
438 (38.5) .430
EIMs at baselineb
Arthritis/arthralgia 1364 (95.1) NA 282
(94.9)
1082 (95.2)
Ocular 33 (2.3) NA 6 (2.0) 27 (2.4)
566 Adv Ther (2018) 35:563–576
have prior anti-TNF use. In contrast, among
patients with EIMs at baseline, patient charac-
teristics were generally similar between placebo
and adalimumab groups with the exception
that significantly more patients receiving pla-
cebo had severe disease activity (50% vs 40%;
P = .001) and prior anti-TNF use (63% vs 48%;
P\.001) versus patients receiving adalimumab
(Table 1).
Proportion of Patients with Resolution
of EIMs
Among patients with any EIM or arthritis/
arthralgia at baseline, resolution occurred in a
significantly greater proportion of adalimumab
versus placebo patients at 6 months (both
P\.001) and 1 year (both P = .008; Fig. 1a, b).
All patients receiving adalimumab with ocular
EIMs at baseline achieved resolution at
6 months (21/21) and 1 year (9/9) compared
with 2/3 and 2/2 patients receiving placebo at
the same time points, respectively. Resolution
of cutaneous EIMs was achieved by 90% (96/
107) of patients receiving adalimumab at
6 months and 95% (35/37) at 1 year versus 3/3
and 2/3 patients receiving placebo, respectively.
A higher proportion of patients receiving adali-
mumab experienced corticosteroid-free EIM res-
olution at 6 months and 1 year compared with
those receiving placebo; more than 60% of
patients receiving adalimumab who were also
taking corticosteroids at baseline had
Fig. 1 Proportion of patients with resolution of a any EIM or b arthritis or arthralgia at 6 months (weeks 20–26) and
1 year (weeks 52–56). P values for between-group comparison from Chi-square test. EIM extraintestinal manifestation
Table 1 continued
Characteristic Overall ITT population Patients with EIMs at baseline
EIMs at
baseline
No EIMs at
baseline
P value Placebo Adalimumab P value
n5 1434 n5 1246 n5 297 n5 1137
Cutaneous 157 (10.9) NA 23 (7.7) 134 (11.8)
Statistical comparison for continuous variables from t test, and categorical variables from Chi-square test
6-MP 6-mercaptopurine, AZA azathioprine, CDAI Crohn’s Disease Activity Index, CRP C-reactive protein, EIM
extraintestinal manifestation, HBI Harvey–Bradshaw Index, ITT intent to treat, NA not applicable, TNF tumor necrosis
factor
a Missing information for 1 placebo patient with EIMs. Disease activity based on the CDAI (moderate disease activ-
ity = CDAI B 300) or HBI (CARE study; moderate disease activity = HBI B 16)
b Patients could have C 1 type of EIM
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corticosteroid-free EIM resolution at 1 year
(Fig. 2).
Time to Resolution of First EIM and Time
to First EIM Recurrence
Compared with patients receiving placebo,
those receiving adalimumab had significantly
shorter median time to resolution of any EIM
and arthritis/arthralgia (both 43 vs 155 days;
P\.001) and cutaneous EIMs (15 vs 52 days;
P = .040; Fig. 3a–c). Among the few patients
with ocular EIMs, median time to resolution of
first EIM was numerically shorter for the adali-
mumab group compared with the placebo
group (19 vs 30 days; P = .073; Fig. 3d). For
patients who achieved initial EIM resolution,
median time to first EIM recurrence was signif-
icantly longer for the adalimumab group versus
the placebo group for any EIM (137 vs 57 days;
P\.001) and for arthritis/arthralgia (141 vs
57 days; P\.001; Fig. 4a, b).
Predictors of Initial EIM Resolution
and First EIM Recurrence
Although several baseline variables were found
to be significant predictors of initial resolution
of any EIM and arthritis/arthralgia, the variables
that showed the greatest difference included
adalimumab treatment and moderate (versus
severe) disease activity (Fig. 5a). The strongest
baseline predictors of EIM recurrence were pla-
cebo treatment and female sex for any EIM and
placebo treatment for arthritis/arthralgia
(Fig. 5b). There were no associations between
initial EIM resolution or EIM recurrence with
baseline smoking status or use of thiopurines,
corticosteroids, or prior anti-TNFs. Furthermore,
disease location was not a significant factor for
EIM resolution. Predictors of resolution and
recurrence of cutaneous and ocular EIMs could
not be estimated because of low event numbers.
DISCUSSION
Arthritis and arthralgia represent the most
common EIMs observed in patients with IBD
[7, 8]; joint symptoms are reported in up to 40%
of patients [23, 24]. This post hoc analysis of
pooled data from 11 adalimumab clinical trials
demonstrated that 54% of patients with mod-
erate to severe CD had at least one EIM at
baseline and significantly more patients receiv-
ing adalimumab achieved resolution of EIMs at
6 months and 1 year versus patients receiving
placebo. Furthermore, arthritis/arthralgia was
present in 51% of patients and represented 95%
of all EIMs reported in these studies. The con-
tribution of arthritis/arthralgia to IBD morbid-
ity is highlighted in that it is the only EIM
included as a component of the IBD disability
index [25]. Of note, most of the data were col-
lected using question 4 of the CDAI, which does
not distinguish between arthritis and arthralgia.
To date, this is the largest study to report the
effects of an anti-TNF agent on EIM resolution
among patients with moderate to severe CD.
Although arthritis and arthralgia are the
most common and likely to be the first pre-
senting EIMs in CD [26], patients can also pre-
sent with a variety of other manifestations.
Erythema nodosum and pyoderma gangreno-
sum are among the most common cutaneous
manifestations reported in CD, with a preva-
lence of 1–13% [2, 26–28], although prevalence
up to 20% has been reported in some studies
[8, 29]. The reported incidence of ocular EIMs
shows an even greater variation between studies
(4–29%) [2, 5, 26]. In this pooled analysis of
patients with moderate to severe CD in
Fig. 2 Proportion of patients with corticosteroid-free
extraintestinal manifestation resolution at 6 months
(weeks 20–26) and 1 year (weeks 52–56)
568 Adv Ther (2018) 35:563–576
adalimumab clinical trials, 6% of patients pre-
sented with cutaneous EIMs and 1% presented
with ocular EIMs.
Recommended therapies for EIMs vary
depending on disease activity and include cor-
ticosteroids, conventional immunosuppres-
sants, non-steroidal anti-inflammatory drugs,
Fig. 3 Time to resolution of ﬁrst EIM in patients with a any EIM, b arthritis or arthralgia, c cutaneous EIMs, and d ocular
EIMs at baseline. ADA adalimumab, EIM extraintestinal manifestation, PBO placebo
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and anti-TNF agents [5]. The benefit of anti-TNF
therapies in the management of EIMs is likely a
result of underlying TNF-a-dependent
pathogenesis, which is common to both IBD
and some comorbid immune-mediated inflam-
matory diseases affecting joints, skin, or eyes
Fig. 3 continued
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[5, 9, 30]. It is unclear if biologic agents that do
not target mediators of systemic inflammation
will have the same impact on EIMs. A recent
post hoc analysis of GEMINI 2 failed to show
a statistically significant benefit of the gut-
selective agent vedolizumab over placebo for
Fig. 4 Median time to ﬁrst EIM recurrence (durable EIM resolution) of a any EIM and b arthritis or arthralgia following
initial resolution. ADA adalimumab, EIM extraintestinal manifestation, PBO placebo
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the treatment of EIMs in patients with CD [31].
In contrast, systemic acting anti-TNF agents
have been shown to successfully treat a variety
of EIMs [32–38]. Furthermore, the first Euro-
pean evidence-based consensus on EIMs in IBD
supports the use of anti-TNFs for the treatment
of several EIMs, including peripheral arthritis,
scleritis/uveitis, erythema nodosum, and pyo-
derma gangrenosum [5].
Data from this analysis support these rec-
ommendations. In our pooled analysis, more
than 50% of patients receiving adalimumab
achieved resolution of any EIM and arthritis/
arthralgia at 6 months and 1 year. Importantly,
in contrast to patients receiving placebo, more
patients receiving adalimumab were able to
discontinue corticosteroids and still achieve
EIM resolution. In addition, the adalimumab
group had significantly shorter time to initial
EIM resolution and longer time to first EIM
recurrence compared with the placebo group.
These findings are consistent with real-world
cohort data. In an open-label study, partial
response or remission of peripheral arthritis was
reported in 61% of patients with CD receiving
adalimumab [39]. Similar findings were repor-
ted in an open-label study of infliximab in
which 61% of patients with CD experienced
improvement of arthritis and 46% achieved
complete resolution at 12 weeks [32].
Increased risk of developing EIMs has been
reported in patients with CD who smoked, had
prolonged disease duration, or were younger at
first diagnosis [3, 8, 40]. Some EIMs (e.g., ery-
thema nodosum) are also reported to affect
women more commonly than men
[8, 27, 28, 40]. Our analysis supports these
findings and demonstrated that significantly
more patients with EIMs at baseline were
female, current smokers, and had severe (versus
moderate) disease activity compared with
patients without EIMs. Patients with EIMs were
also more likely to be older and have longer
disease duration. Predictors of initial and
Fig. 5 Predictors of a EIM resolution and b ﬁrst EIM
recurrence. Hazard ratio (95% CI) for time to ﬁrst
resolution or ﬁrst recurrence. P value from a Cox model.
ADA adalimumab, CRP C-reactive protein, EIM
extraintestinal manifestation, PBO placebo, TNF tumor
necrosis factor. Asterisk indicates ileal, colonic, gastroduo-
denal versus other
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durable EIM resolution included adalimumab
treatment, male sex, and moderate (versus sev-
ere) disease activity at baseline. We did not find
an association between resolution of EIMs and
smoking status. Because of the large size of this
study, other variables were found to be statisti-
cally significant but may not be clinically
meaningful.
There were a few limitations in this analysis.
First, this was a post hoc analysis of trials with
different study designs (including both ran-
domized and open-label trials). Per study
designs, the duration of placebo exposure was
limited in many trials, leading to an imbalanced
number of evaluable patients at 6 months and
1 year. In addition, given that only a small
proportion of patients had ocular or cutaneous
EIMs at baseline, it was difficult to evaluate the
full contribution of adalimumab to resolution
of these EIMs. Finally, in the studies that used
the CDAI, we were able to analyze the general
category of EIMs (e.g., ocular or cutaneous) but
not specific EIMs within each category. Conse-
quently, inclusion of arthralgia, which is com-
mon in the general population, may have
overestimated the efficacy reported in the
arthritis/arthralgia category versus assessing
arthritis alone. Furthermore, as a result of the
way EIMs were captured in the clinical trials
assessed, it was not possible to differentiate
between arthropathies that are independent or
dependent of disease activity.
CONCLUSION
This pooled analysis of more than 2000 patients
with moderate to severe CD demonstrated that
treatment with adalimumab was effective in
initial and durable resolution of any EIM and
arthritis and/or arthralgia.
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